
Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The secret appeal of Harlan Coben’s messy, addictive TV thrillers - 2
Instructions to Guarantee Kids Foster Solid Dental Propensities - 3
This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026 - 4
Step by step instructions to Involve Compact disc Rates for Magnanimous Giving - 5
The Way to Business: Startup Illustrations Learned
'Here we go again': Businesses grapple with fuel costs
Nitty gritty Manual for Picking Agreeable Tennis shoes
Moderna to complete US mRNA manufacturing network with $140 million investment
As tetanus vaccination rates decline, doctors worry about rising case numbers
Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
How food assistance programs can feed families and nourish their dignity
'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.













